Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver
Status unconfirmed · Phase 3
Conditions studied: Melanoma (Skin), Metastatic Cancer
In brief
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Histamine dihydrochloride may help interleukin-2 kill more tumor cells by making tumor cells more sensitive to the drug. It is not yet known if interleukin-2 is more effective with or without histamine dihydrochloride in treating stage IV melanoma that is metastatic to the liver. PURPOSE: Randomized phase III trial to compare the effectiveness of interleukin-2 with or without histamine dihydrochloride in treating patients who have stage IV melanoma that is metastatic to the liver.
Key facts
- Study ID
- NCT00039234
- Run by
- Maxim Pharmaceuticals
- Starts
- 2002-09-01
- Last updated by the study team
- 2013-12-18
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- John Wayne Cancer Institute at Saint John's Health Center — Santa Monica, California, United States
- University of Colorado Cancer Center at University of Colorado Health Sciences Center — Aurora, Colorado, United States
- Moffitt Clinic at Tampa General Hospital — Tampa, Florida, United States
- University of Chicago Cancer Research Center — Chicago, Illinois, United States
- James Graham Brown Cancer Center at University of Louisville — Louisville, Kentucky, United States
- Ellis Fischel Cancer Center at University of Missouri - Columbia — Columbia, Missouri, United States
- Melanoma Center of St. Louis, Missouri Baptist Medical Center — St Louis, Missouri, United States
- Beth Israel Medical Center — New York, New York, United States
- Memorial Sloan-Kettering Cancer Center — New York, New York, United States
- Comprehensive Cancer Center at Our Lady of Mercy Medical Center — The Bronx, New York, United States
- Hillman Cancer Center at University of Pittsburgh Cancer Institute — Pittsburgh, Pennsylvania, United States
- Cross Cancer Institute — Edmonton, Alberta, Canada
- Centre Hospitalier Universitaire de Quebec — Québec, Quebec, Canada
- Charite - Universitaetsmedizin Berlin — Berlin, Germany
- Universitatsklinik - Saarland — Homburg/Saar, Germany
- Kiel Universitatshautklinik — Kiel, Germany
- Klinische Kooperationseinheit fur Dermatoonkologie (DFKZ) — Mannheim, Germany
- Klinikum Rechts Der Isar/Technische Universitaet Muenchen — Munich, Germany
- Royal Marsden Hospital - Sutton — London, England, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.